Back to search results

Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications after Liver Transplant

This study is looking at the safety of using a treatment called autologous Adipose-Derived Mesenchymal Stromal Cells (AMSC) during a living donor liver transplant. AMSC are special cells taken from your own body fat. Researchers want to see if applying these cells to the area where the new liver is connected (the biliary anastomosis) can help prevent problems with the bile ducts after surgery. This study is for adults aged 18 to 65 who are scheduled for a living donor liver transplant. The main goal is to track any side effects for up to 24 months after the treatment. The study plans to enroll 20 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for side effects for 24 months after the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06649864

Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications

Not Yet Recruiting
PHASE1Ages 18–65InterventionalTreatment
Mayo Clinic
~20 participants
Updated 2026-04-06 on ClinicalTrials.gov
What's tested:Autologous adipose derived mesenchymal stromal cells (AMSC)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Side effects
Measured over 24 months

Conditions

Liver Transplant; Complications
Liver Diseases

Explore related trials

Chronic Renal FailureLiver Transplantation

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Julie Heimbach · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Jackie Reiter
[email protected]
507-538-2224
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Listed for liver transplantation
Non-pediatric patients with a planned LDLT
Ability to communicate with investigative staff
Competence to give written informed consent
Ability to comply with the entire study procedure
All sexes and genders will be eligible for the study

Exclusion

Planned deceased donor liver transplantation
Uncontrolled / unresolved local or systemic infection
Body mass index \> 40
Planned pancreaticoduodenectomy or sleeve gastrectomy
Anticipation of 3 biliary anastomoses (we will include those anticipated to have 1 or 2 biliary anastomoses as detailed below)
Pregnancy or breastfeeding
Non-liver cancers (we will include certain patients with primary liver cancer as detailed below)
Treatment with any investigational drug / device within 60 days prior to study entry
Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs
Patients who are employees or relatives of the investigator

What this trial measures

  • Side effects24 months

    Number of subjects to experience systemic symptoms, irritation, inflammation, infections or biliary obstructions